|
× |
 |
POLYVINYL ACETATE PHTHALATE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
BAXDELA (delafloxacin meglumine) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
XYLITOL Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
POLYETHYLENE GLYCOL Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
GLYCERYL MONOSTEARATE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
XDEMVY (lotilaner) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
XARELTO (rivaroxaban) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
DALVANCE (dalbavancin hydrochloride) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
× |
 |
VIBATIV (telavancin hydrochloride) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
|
|